Puma Biotechnology Inc (NASDAQ:PBYI) has received a consensus recommendation of “Hold” from the thirteen brokerages that are covering the stock, MarketBeat reports. Three investment analysts have rated the stock with a sell rating and ten have assigned a hold rating to the company. The average twelve-month price objective among analysts that have issued ratings on the stock in the last year is $19.25.
Several research firms recently issued reports on PBYI. Cowen reissued a “hold” rating and issued a $25.00 target price on shares of Puma Biotechnology in a research report on Friday, August 9th. BidaskClub raised Puma Biotechnology from a “sell” rating to a “hold” rating in a research report on Tuesday. Cantor Fitzgerald downgraded Puma Biotechnology from an “overweight” rating to a “neutral” rating and cut their target price for the company from $57.00 to $20.00 in a research report on Friday, May 10th. Barclays cut their price target on Puma Biotechnology from $21.00 to $9.00 and set an “underweight” rating on the stock in a research report on Friday, August 9th. Finally, ValuEngine raised Puma Biotechnology from a “sell” rating to a “hold” rating in a research report on Thursday, August 1st.
In other Puma Biotechnology news, insider Alan H. Auerbach sold 12,715 shares of the stock in a transaction dated Monday, July 22nd. The stock was sold at an average price of $9.98, for a total transaction of $126,895.70. Following the sale, the insider now directly owns 4,189,525 shares of the company’s stock, valued at approximately $41,811,459.50. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Insiders have sold a total of 14,299 shares of company stock worth $146,360 over the last ninety days. 21.80% of the stock is owned by insiders.
Institutional investors and hedge funds have recently made changes to their positions in the business. SG Americas Securities LLC purchased a new stake in shares of Puma Biotechnology during the 1st quarter worth about $210,000. Pictet Asset Management Ltd. boosted its stake in shares of Puma Biotechnology by 53.3% during the 1st quarter. Pictet Asset Management Ltd. now owns 118,800 shares of the biopharmaceutical company’s stock worth $4,608,000 after acquiring an additional 41,300 shares in the last quarter. Norges Bank purchased a new stake in shares of Puma Biotechnology during the 4th quarter worth about $13,719,000. Spark Investment Management LLC boosted its stake in shares of Puma Biotechnology by 20.4% during the 1st quarter. Spark Investment Management LLC now owns 570,800 shares of the biopharmaceutical company’s stock worth $22,141,000 after acquiring an additional 96,700 shares in the last quarter. Finally, Sivik Global Healthcare LLC purchased a new stake in shares of Puma Biotechnology during the 1st quarter worth about $1,552,000. 81.41% of the stock is currently owned by institutional investors.
Shares of NASDAQ PBYI traded down $0.40 during mid-day trading on Friday, hitting $9.65. The stock had a trading volume of 37,202 shares, compared to its average volume of 1,692,193. The company has a debt-to-equity ratio of 4.08, a quick ratio of 2.50 and a current ratio of 2.53. The stock’s 50 day moving average price is $10.82. Puma Biotechnology has a twelve month low of $8.45 and a twelve month high of $50.75. The stock has a market cap of $431.37 million, a price-to-earnings ratio of -3.21 and a beta of 1.73.
Puma Biotechnology (NASDAQ:PBYI) last released its earnings results on Thursday, August 8th. The biopharmaceutical company reported ($0.97) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.90) by ($0.07). Puma Biotechnology had a negative net margin of 32.23% and a negative return on equity of 224.11%. The firm had revenue of $53.90 million during the quarter, compared to analyst estimates of $53.40 million. During the same period in the previous year, the company earned ($0.59) earnings per share. Puma Biotechnology’s revenue was up 6.1% on a year-over-year basis. On average, equities research analysts expect that Puma Biotechnology will post -2.48 EPS for the current fiscal year.
Puma Biotechnology Company Profile
Puma Biotechnology, Inc, a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care. Its drug candidates include PB272 neratinib (oral) for the treatment of early stage breast cancer, metastatic breast cancer, non-small cell lung cancer, HER2 mutation-positive solid tumors, and HER2-mutated non-amplified breast cancer; and PB272 neratinib (intravenous).
Further Reading: What is Blockchain?
Receive News & Ratings for Puma Biotechnology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Puma Biotechnology and related companies with MarketBeat.com's FREE daily email newsletter.